<DOC>
	<DOCNO>NCT02716519</DOCNO>
	<brief_summary>This study design assess comparative effectiveness SANTYL® versus standard care treatment pressure ulcer diabetic foot ulcer within continuum care ACO . After meet study criterion , participant randomly assign apply Santyl standard care pressure ulcer diabetic foot ulcer 6 week . Participants follow one year date randomization ass ulcer status ulcer complication .</brief_summary>
	<brief_title>Use Santyl Within Accountable Care Organization</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Pressure Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Provide write informed consent , consist reading , signing , date informed consent document Investigator , subInvestigator designate study staff member explain study procedure , risk , contact information . 2 . Eighteen ( 18 ) year age old , either sex , race skin type . 3 . Willing able make require study visit . 4 . Able follow instruction perform dress change home caregiver perform dressing change accord protocol . 5 . Subject currently treat inpatient acute care set . 6 . Willing use appropriate offloading device keep weight foot ulcer ; currently receive adequate pressure redistribution accord local protocol affect area pressure ulcer . 7 . For DFU : An ulcer present part plantar surface foot plantar surface hallux 0.5 cm2 10 cm2 inclusive ( measure Screening Visit use ARANZ Silhouette image device ) . For PU : Stage IIIV ulcer 1 cm2 64 cm2 inclusive ( measure Screening Visit use ARANZ Silhouette image device ) . Subjects may one ulcer without limitation ulcer burden , one qualify ulcer per subject select study ( selection base great clinical need , determine Investigator ) . 8 . For low extremity ulcer : Adequate arterial blood flow evidence ankle brachial index ( ABI ) &gt; 0.70 ≤ 1.2 . If ABI &gt; 1.2 , perfusion near site ulcer must confirm : i.e. , foot warm touch palpable pulse . Availability ABI complete within 90 day Screening acceptable . 9 . Separation least 5 cm ( close ulcer edge close ulcer edge ) measure use ARANZ Silhouette image device ≥ 2 ulcer present . 10 . Target ulcer infect base clinical assessment . EXCLUSION CRITERIA 1 . Contraindications hypersensitivity use clostridial collagenase . 2 . Participation another clinical trial within thirty ( 30 ) day Screening , plan participation overlapping study . 3 . Bleeding disorder would preclude sharp debridement study . 4 . Active cellulitis target ulcer , lymphangitic streaking , deep tissue abscess , infection muscle , tendon , joint bone . 5 . Comorbidities lead systemic organ dysfunction severe single multiorgan failure opinion Investigator would preclude safe subject participation study . 6 . A target ulcer involve underlie tissue tendon . 7 . Diagnosis chronic granulomatous disease , leukocyte adhesion defect , severe neutropenia . 8 . Current treatment ( time Screening Visit ) following : Systemic corticosteroid . If corticosteroid treatment ≥ 10 day , must 1 week interval discontinuation screening . Immunosuppressive agent Chemotherapeutic agent Antiviral agent Systemic antibiotic therapy acute woundrelated infection Topical antibiotic treatment target ulcer 9 . Treatment target ulcer bioactive therapy within 1 month screening : Plateletderived growth factor ( e.g. , Regranex ) Cellular Tissuebased Products ( e.g. , Apligraf , Dermagraft , Integra , Oasis , etc . ) Amniotic membrane product ( e.g. , EpiFix , Grafix , etc . ) 10 . Prior treatment target ulcer length time CCO ( SANTYL ) within 30 day screen . 11 . Any prior radiation therapy affect area 12 . Medical physical condition , opinion Investigator , would preclude safe subject participation study . 13 . Blood count blood chemistry value follow : NOTE : Availability lab result within 30 day Screening acceptable . Alanine aminotransferase ( ALT ) &gt; 3x upper limit normal Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal Gamma Glutamyl Transferase ( GGT ) &gt; 2.5x upper limit normal Serum albumin &lt; 2.0 g/dL Prealbumin level &lt; 10 mg/dL Alkaline phosphatase &gt; 500 U/L Serum total bilirubin &gt; 3.0 mg/dL Serum BUN &gt; 75 mg/dL Serum creatinine &gt; 4.5 mg/dL HbA1c &gt; 12 % Hemoglobin ( Hgb ) &lt; 8.0 g/dL WBC &lt; 2.0 x 109/L Absolute neutrophil count &lt; 1.0 x 109/L Platelet count &lt; 50 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>diabetic foot ulcer</keyword>
	<keyword>foot sore</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>DFU</keyword>
	<keyword>pressure ulcer</keyword>
	<keyword>bed sore</keyword>
</DOC>